Xyz future or investigational therapies

Jump to navigation Jump to search

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Xyz future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Xyz future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Xyz future or investigational therapies

CDC on Xyz future or investigational therapies

Xyz future or investigational therapies in the news

Blogs on Xyz future or investigational therapies

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Xyz future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rates have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.

Future or Investigational Therapies

  • MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rates have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.

References

Template:WH Template:WS